Since its creation as the National Heart Institute in 1948, the National Heart, Lung, and Blood Institute (NHLBI) has led a national biomedical research program in heart, lung, blood, and blood vessel diseases, and has become increasingly involved in complex clinical trials to validate its research findings. In addition, NHLBI sponsors demonstrations and educational activities to apply proved research findings in the health care community.
volved in complex research validation exercises (clinical trials). Over the past 5-7 years, it has embarked on demonstration and educational activities aimed at expediting the translation of proved research results into practical measures that can be applied in the community to improve the health and well-being of our citizens.
There are four major events in the history of the NHLBI. The first occurred in June 1948, when President Harry S. Truman signed the National Heart Act, creating the National Heart Institute. The second was in 1969, when the Heart Institute was redesignated the National Heart and Lung Institute, and its responsibilities were extended to include disorders of the lung. The third occurred in 1972, with the passage of the National Heart, Blood Vessel, Lung, and Blood Act. That Act broadened and expanded the Institute's national program in heart, lung and blood diseases, and gave more responsibility to the Institute for coordinating and planning an intensified national attack on these diseases. It is responsible for the present broad scope of Institute activities and for shaping its present Grganizational structure. It also led, in 1976, to the Institute's renaming as the NHLBIa name change that recognized its new responsibilities in the areas of blood disease and blood banking.
The NHLBI thus has grown significantly in mission and mandate over the past 30 years. This growth can be measured in other terms as well. In 1950, the Institute received its first annual appropriation, totaling $16 million; in 1978, its annual If there were ever any doubts as to where in the biomedical research spectrum the Institute's primary responsibilities lay, Congress dispelled them in the National Heart, Blood Vessel, Lung, and Blood Act of 1972. As specified in that law, the Institute was to be responsible for basic research, applied research, clinical investigation, clinical trials and other validation activities, together with demonstration and education activities involving both the health care community and the general public in sum, the en-
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In its approaches to these responsibilities, the Institute's activities can usually be grouped into three categories. One category comprises actions that require acquisition of new and basic information. Second, there are actions that draw upon existing information but require further testing and evaluation before they can be properly applied, such as validation activities (clinical trials). Third, there are actions that National Heart, Lung, and Blood Institute I I 1556 CIRCULATION CVD PREVENTION/Levy can be applied now for the better prevention, detection and treatment of disease. These include research translation activities as well as education and demonstration projects for health professionals and the public.
Of the five divisions of the NHLBI, the Division of Heart and Vascular Diseases is the direct descendant of the old National Heart Institute and is responsible for 10 research program areas. Four of these program areas focus on major etiological processes: atherosclerosis, hypertension, congenital and rheumatic heart disease and cardiomyopathies, and infections of the heart. Three are concerned with clinical syndromes resulting from these basic processes: coronary, peripheral and cerebral vascular disease. Two are concerned with sequelae of these problems: arrhythmia, heart failure and shock. The tenth, concerned with circulatory assistance, was formerly known as the Artificial Heart Program.
Perhaps the best way to appreciate the tremendous progress of the past 30 years is to compare what we could do for the heart patient in 1948 with what can be done today.
In rheumatic heart disease, it was known in 1949 that penicillin could reduce the incidence of rheumatic fever. But once rheumatic heart disease occurred, little could be done for the patient, especially when heart valves were damaged. In congenital heart disease, we could taxonomically define 38 different types of defects, but we could do little to correct them. The cardiac surgery that could be attempted usually required the surgeon to work by feel alone in a blooddrenched operative field that writhed and twisted with each heartbeat. The prospects for success were low and operative mortality was high.
In 1953 that the heart-lung machine was introduced, as was hypothermia. These and other lifesupport techniques developed during the 1950s and 1960s provided surgeons with prolonged access to widely opened, stilled hearts. Coupled with the development of reliable artificial valves and a variety of other prostheses, they permitted surgeons to correct and palliate even complex or multiple congenital malformations and to repair or replace heart valves heavily damaged by rheumatic fever. Meanwhile, safer and more sensitive diagnostic procedures were being developed for detecting congenital or acquired heart defects and for assessing their effects on heart performance, permitting sound decisions as to whether corrective surgery was necessary and, if so, wuhen it should be performed. They also provided detailed anatomic and physiologic information that often enabled surgeons to plan their procedures in great detail and to allow for most contingencies even before the patient's chest was opened. As a result of these advances, the success rate of surgical interventions has steadily increased, and the risk that inevitably attends any open heart procedure has steadily declined, even for neonates and for patients older than 65 years. From time to time, ingenious techniques have been developed that have provided nonsurgical solutions to what had previously been surgical problems. For example, closure of the patent ductus arteriosus in newborn infants can sometimes be achieved medically by administering prostaglandin inhibitors. Very recently, an umbrella-like prosthetic device that, in the closed position, can be threaded into the heart via a catheter, then opened and affixed by hooks to heart tissues, has provided satisfactory closure of atrial or ventricular septal defects in young children.
Largely because of spectacular advances in cardiovascular diagnosis and surgery over the past 30 years, the mortality rate for congenital heart disease has declined by 38% and the mortality rate for rheumatic heart disease has declined by some 65% since 1948.
In the case of hypertension and hypertensive heart disease, the lot of the afflicted patient was indeed an unhappy one in 1948. Treatment was usually started only after serious signs or symptoms had appeared. Rice diets or other regimens of drastically curtailed sodium intake, though unpalatable and difficult to follow, worked in some cases. Few drugs were available for blood pressure control, and most had serious or highly unpleasant side effects.
In the 1950s, new drugs came into clinical use. Perhaps the most important of these were the thiazide diuretics, introduced in 1957, which helped the body eliminate excess salt and water. Other new drugs were introduced, and old drugs like the tranquilizer reserpine found new use in controlling hypertension.
In the 1960s, clinical trials were conducted to show not only that we could achieve and maintain good blood pressure control with these drugs, but that adequate treatment prevented stroke, renal failure and heart failure. In 1972, Elliot Richardson, then Secreatry of Health, Education, and Welfare, began the National High Blood Pressure Education Program, which has been coordinated by the NHLBI. Its goals were to increase awareness of the public that high blood pressure was common; that it affected over 23 million Americans; that it was often asymptomatic, but could lead to serious health problems; that it could be treated, and that treatment could prevent such sequelae as stroke, heart failure, renal failure and, probably, heart attack as well.
Since 1948, the mortality rate for hypertension has fallen by 80%. The mortality rate from stroke, one of the more serious sequelae of high blood pressure, has declined approximately 36% over this period, with the steepest decline occurring in the last 51/2 years.
Coronary artery disease, in 1948 as now, is the major killer, responsible for over 600,000 deaths each year. For the heart attack victim, therapy then involved not rocking any boats. Hospitalization was prolonged. Now there are new, more aggressive concepts of acute coronary care. The first goal is to get the patient into the medical care system as quickly as possible. Once this is done, we can monitor and control life-threatening disturbances in heart rhythm, and if the heart should stop, we can start it again. We can prevent further heart muscle damage and decrease the amount of permanent damage that occurs. We can treat and prevent incipient heart failure. We have resuscitative equipment that was not even dreamed of in 1948. We have artificial pacemakers for the immediate or long-term control of heartbeat and better drugs for the treatment of coronary insufficiency.
However, we have also realized that even such a powerful armamentarium as this may be too little or may be too late. In about one-fourth of patients with coronary artery disease, the first overt sign of the disease may also be the last, and sudden death may occur an acute heart attack or violent arrhythmia that kills the patient before he can reach or be reached by medical care. Thus, we are seeking and developing techniques for earlier diagnosissafe, noninvasive techniques that will detect coronary artery disease long before signs or symptoms become manifest.
Of great importance to prevention and early diagnosis has been the work of cardiovascular epidemiologists, such as those involved in the Framingham, Tecumseh and Chicago heart projects. Their research has defined cardiovascular risk factors, traits or habits that put the individual at increased risk of developing premature coronary heart disease or experiencing its potentially lethal complications. This information allows physicians to spot highly susceptible subjects early and to initiate measures against modifiable risk factors. It also appears that a large segment of the public is responding to this information and voluntarily altering potentially hazardous traits, habits and modes of life.
The mortality rate for coronary heart disease increased steadily during the 1950s, but then plateaued in the 1960s. Since 1968, it has decreased by more than 16%. 1960-1976.70 97 monitoring; surgical repair of prosthetic replacement of diseased blood vessels; surgical repair of the heart; new concepts of coronary and intensive care; drug therapy for hypertension; chemotherapy and antibiotics to prevent or treat rheumatic fever and infectious heart disease; and recognition and increased public awareness of cardiovascular risk factors.
With all this, cardiovascular mortality has decreased over 30% in the last 30 years, and this decline has been acceerating'so much that 60%37 of it has occurred over the past 10 years (fig. 3 ). This decline is clearly due to the increasingly effective armamentarium for treatment, both medically and surgically, and also to increased public awareness of and attention to risk factors.
Not only is the declining death rate a clear sign that the battle against cardiovascular disease is being won, . 4) . These had held fairly steady for several decades after the eradication of typhoid fever and other widespread infectious diseases that once ravaged the country. Then around 1970, and coinciding with observed decreases in cardiovascular disease mortality, there was an abrupt upturn in the projected life expectancy for all citizens. This upturn applies to males and females as well as to minority and majority populations, and it has been dramatic. For example, the life expectancy for black males has increased by more than 3 years since 1973. But what of the future? What does it portend? Striking, amazing advances through research have been made in the last 30 years. It is clear that there will be many more. There is no cardiovascular disease or problem that is so complicated that it cannot be attacked, understood and ultimately remedied, but at what price? The NHLBI is focusing increased attention on primary prevention as the only truly cost-effective approach. Waiting to repair or palliate may be too late and is actually more costly.
Primary prevention implies educating physicians and the public about risk factors: the cessation of smoking, the treatment of high blood pressure, the need for all Americans to assume responsibility for their own health maintenance behavior. Primary prevention also means increased support for basic research to define the etiology and pathophysiology of two primary processes still incompletely understood arteriosclerosis and hypertension. It means the expeditious validation and translation of pertinent new findings emerging from such studies. Thus, prevention of cardiovascular disease includes research through the entire spectrum aimed at averting premature cardiovascular disease, since treatment and palliation are so costly, not only in terms of resources and dollars, but also in terms of human suffering.
As we increase our awareness of the basic processes behind arteriosclerosis and hypertension, we should move ever closer to preventing these diseases and their sequelae. The prevention of premature cardiovascular diseases is the prospect for the future.
Research Related to Underyling Mechanisms in Atherosclerosis DANIEL STEINBERG, M.D., PH.D.
SUMMARY A brief resume of advances in atherosclerosis research over the past 30 years is presented, emphasizing the multidisciplinary origins of those advances. A somewhat more detailed review of progress in the lipoprotein field is presented as an example to illustrate the pace of research related to atherosclerosis. Finally, an attempt is made to identify some of the research areas that promise to yield valuable new insights in the next 30 years.
IN RECENT YEARS there has been a convergence of research advances from several directions, a coupling of concepts from different disciplines. As a result we are able to formulate more 'specific, more coherent, testable hypotheses about atherogenesis. Some aspects of these hypotheses are strongly supported by experimental evidence. These hypotheses are not necessarily mutually exclusive; there is reason to believe that there is more than one cause of atherosclerosis, and there may not be a "final com- mon path." Atherosclerosis is, in fact, a disease of multiple interactive etiologies,' and prevention may well require intervention along different lines.
Advances Over the Past 30 Years

Documentation of Risk Factors
The documentation by epidemiologists of the risk factors in atherosclerosis has been a landmark of the past 30 years.2 These risk factors have been discussed in detail3 (table 1) . There has been important interaction between the epidemiologic approach and the approaches at the basic level. For example, the well-documented epidemiologic finding that women, during their reproductive years, enjoy a relatively protected status has stimulated research on the effects of estrogenic hormones on lipoprotein metabolism and more recently on the local metabolism of arterial tissue. The more rapid progression of lesions and the excess coronary heart disease mortality in cigarette
